NEWS
Artelo Biosciences Presents Important New Data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, presented new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society. The conference took place from June 4-6, 2024, in Nottingham, UK. ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor, showed efficacy in reducing breast cancer-induced bone pain and diabetic neuropathy in preclinical models. Effective doses and plasma exposures were consistent with previous data. Artelo plans to submit an Investigational New Drug application to the U.S. FDA this month. This non-opioid, non-steroidal treatment is seen as a promising alternative for pain management.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment